Acrux Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Michael Kotsanis

Algemeen directeur

AU$702.0k

Totale compensatie

Percentage CEO-salaris	68.4%
Dienstverband CEO	10yrs
Eigendom CEO	0.5%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	10yrs

Recente managementupdates

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Nov 16

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Nov 16

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

Nov 16

Analyse CEO-vergoeding

Hoe is Michael Kotsanis's beloning veranderd ten opzichte van Acrux's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$702k	AU$480k	-AU$6m
Mar 31 2024	n/a	n/a	-AU$3m
Dec 31 2023	n/a	n/a	-AU$709k
Sep 30 2023	n/a	n/a	-AU$736k
Jun 30 2023	AU$710k	AU$463k	-AU$764k
Mar 31 2023	n/a	n/a	-AU$4m
Dec 31 2022	n/a	n/a	-AU$8m
Sep 30 2022	n/a	n/a	-AU$9m
Jun 30 2022	AU$670k	AU$446k	-AU$10m
Mar 31 2022	n/a	n/a	-AU$10m
Dec 31 2021	n/a	n/a	-AU$10m
Sep 30 2021	n/a	n/a	-AU$11m
Jun 30 2021	AU$645k	AU$468k	-AU$13m
Mar 31 2021	n/a	n/a	-AU$12m
Dec 31 2020	n/a	n/a	-AU$11m
Sep 30 2020	n/a	n/a	-AU$10m
Jun 30 2020	AU$510k	AU$452k	-AU$9m
Mar 31 2020	n/a	n/a	-AU$10m
Dec 31 2019	n/a	n/a	-AU$11m
Sep 30 2019	n/a	n/a	-AU$10m
Jun 30 2019	AU$521k	AU$451k	-AU$8m
Mar 31 2019	n/a	n/a	-AU$9m
Dec 31 2018	n/a	n/a	-AU$9m
Sep 30 2018	n/a	n/a	-AU$12m
Jun 30 2018	AU$690k	AU$406k	-AU$14m

Compensatie versus markt: De totale vergoeding ($USD 465.61K ) Michael } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 304.34K ).

Compensatie versus inkomsten: De vergoeding van Michael is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Michael Kotsanis (58 yo)

10yrs

Tenure

AU$701,959

Compensatie

Mr. Michael John Kotsanis, BSc, GradDipBus, MBus has been Chief Executive Officer and Managing Director of Acrux Limited since November 03, 2014. He served as an Independent Non-Executive Director at IDT A...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Kotsanis	CEO, MD & Executive Director	10yrs	AU$701.96k	0.52% A$ 74.0k
Geoffrey Edward Brooke	Independent Non-Executive Director	8.4yrs	AU$84.65k	0.58% A$ 82.8k
Ross Dobinson	Independent Non-Executive Chairman	26.7yrs	AU$131.11k	1.81% A$ 257.2k
Timothy Oldham	Independent Non-Executive Director	11.1yrs	AU$84.65k	0.52% A$ 74.5k
Donald Brumley	Independent Non-Executive Director	3.4yrs	AU$84.01k	1.17% A$ 166.4k

10.0yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ACR zijn ervaren en ervaren (gemiddelde ambtstermijn van 10 jaar).

Acrux Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Acrux Limited, Annual General Meeting, Nov 21, 2024

Insufficient new directors

Acrux Limited, Annual General Meeting, Nov 29, 2023

Independent Non-Executive Director recently bought AU$92k worth of stock

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Acrux Limited, Annual General Meeting, Nov 23, 2022

Recent updates

New major risk - Market cap size

Acrux Limited, Annual General Meeting, Nov 21, 2024

New major risk - Financial position

Full year 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

First half 2024 earnings released: AU$0.011 loss per share (vs AU$0.011 loss in 1H 2023)

Acrux Limited to Report First Half, 2024 Results on Feb 23, 2024

Acrux Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.035 loss in FY 2022)

New minor risk - Financial data availability

New minor risk - Share price stability

Independent Non-Executive Director recently bought AU$92k worth of stock

First half 2023 earnings released: AU$0.011 loss per share (vs AU$0.019 loss in 1H 2022)

Acrux and Padagis Announce the Launch of Prilocaine and Lidocaine Cream in the United States

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Acrux Limited, Annual General Meeting, Nov 23, 2022

Full year 2022 earnings released: AU$0.035 loss per share (vs AU$0.057 loss in FY 2021)

Acrux's Sixth Generic Dossier Accepted by FDA for Review

Less than half of directors are independent

Non-Executive Director recently bought AU$89k worth of stock

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Acrux Limited Announces Fifth Generic Dossier Accepted by FDA for Review

Acrux Limited Launches Testosterone Topical Solution USP, 30mg Per Actuation

Full year 2021 earnings released: AU$0.057 loss per share (vs AU$0.056 loss in FY 2020)

CFO & Company Secretary Deborah Ambrosini has left the company

Acrux Receives Approval from the FDA for Its Generic Version of Jublia

Non Executive Director Norman Gray has left the company

Acrux Confirms Patent Challenge

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Acrux Limited Announces the US Food and Drug Administration Approves its Generic Product Based on Perrigo's Testosterone Topical Solution, 30mg/1.5mL

New 90-day high: AU$0.21

Acrux Limited announced that it expects to receive AUD 7.815143 million in funding from Bioscience Managers Pty Ltd and other investors

Here's What We Think About Acrux's (ASX:ACR) CEO Pay

Acrux Limited Signs Licensing Agreement with Dash Pharmaceuticals

Full year earnings released - AU$0.057 loss per share

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd